AstraZeneca PLC filed a Form 6-K on 16 November 2026 disclosing that the U.S. Food and Drug Administration approved Imfinzi (durvalumab) in combination with enfortumab vedotin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy, for adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy.

Key Highlights

  • FDA approval granted: Perioperative Imfinzi plus neoadjuvant enfortumab vedotin received U.S. approval for cisplatin-ineligible or cisplatin-refusing adult patients with muscle-invasive bladder cancer.
  • Event-free survival benefit: The VOLGA Phase III trial showed a 49% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm (EFS hazard ratio 0.51; 95% CI 0.38-0.67; p<0.0001).
  • Overall survival benefit: The Imfinzi combination reduced the risk of death by 42% compared to the comparator arm (OS hazard ratio 0.58; 95% CI 0.40-0.83; p=0.0027).
  • Two-year survival rates: An estimated 78% of patients in the Imfinzi combination arm were alive at two years, compared to 69% in the comparator arm.
  • Grade 3/4 adverse events: Grade 3 and 4 adverse events due to any cause occurred in 64% of patients in the Imfinzi combination arm and 44% in the comparator arm.
  • Trial scale: The VOLGA trial randomised 695 patients across 182 centres in 25 countries.
  • Third bladder cancer indication: According to the filing, this approval represents AstraZeneca's third bladder cancer indication in two years for Imfinzi.

VOLGA Trial Data Underlying AstraZeneca's MIBC Approval

According to the filing, the FDA granted the approval after the application secured Priority Review. The approval was based on results from the VOLGA Phase III trial, which were presented during a Presidential Symposium at the 2026 European Society for Medical Oncology Congress and simultaneously published in The New England Journal of Medicine. The trial enrolled patients with muscle-invasive bladder cancer who were ineligible for or had refused cisplatin-based chemotherapy, a population the filing notes represents as many as 50% of MIBC patients.

In the VOLGA trial, the approved regimen consisted of three cycles of Imfinzi and enfortumab vedotin before radical cystectomy, followed by nine cycles of Imfinzi adjuvant monotherapy. The filing reports that estimated median event-free survival was not yet reached for the Imfinzi combination, compared to 12.1 months for the comparator arm. An estimated 64% of patients in the Imfinzi combination arm remained alive and event-free at two years, versus 45% in the comparator arm. Estimated median overall survival was not yet reached in either arm at the time of the interim analysis.

The filing states the safety and tolerability of Imfinzi plus enfortumab vedotin was "consistent with the known safety profiles of the individual medicines, with no new safety signals identified," and that patient-reported quality of life was maintained after surgery in patients treated with the Imfinzi combination. The filing also notes that regulatory applications are currently under review in the European Union, Japan, and several other countries based on the VOLGA trial results. AstraZeneca PLC trades on NYSE as NYSE:AZN.

What Was Disclosed

AstraZeneca disclosed an FDA approval for a perioperative Imfinzi regimen with neoadjuvant enfortumab vedotin in cisplatin-ineligible muscle-invasive bladder cancer patients, based on VOLGA Phase III data showing statistically significant reductions in disease recurrence risk and risk of death.